February 26th 2013
Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.
January 18th 2012
Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven
December 22nd 2011
Dr. Linda Vahdat, from the New York-Presbyterian Hospital, Compares Halaven and Ixempra Neuropathy